Clinical Trial: Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated Dyskinesia

U.S., Oct. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07905976) titled 'Safety and Tolerability of Single and Repeated Dose of IMM02-KORA in PD-associated Dyskinesia' on Oct. 15.

Brief Summary: The goal of this clinical trial is to test Safety and tolerability of single and repeated dose of IMM02-KORA in subjects with PD-associated dyskinesia.

Study Start Date: Nov. 30

Study Type: INTERVENTIONAL

Condition: Dyskinesia, Medication-induced Dyskinesia, Drug-Induced

Intervention: DRUG: IMM02-KORA

IMM02-KORA (nalfurafine hydrochloride) is a synthetic selective kappa opioid receptor agonist (KORA).

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Immunis, Inc.

Disclaimer: Curated by HT Syndication....